Ferzapin

Composition

Ferzapin 5 mg: Each uncoated tablet contains: olanzapine USP – 5 mg
Ferzapin 10 mg: Each uncoated tablet contains: olanzapine USP – 10 mg.

Indications for use

• Treatment of schizophrenia
• Effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response
• Treatment of moderate to severe manic episode
• Prevention of recurrence in patients with bipolar disorder.

Mode of application

Adults:
Schizophrenia: The recommended starting dose for Ferzapin is 10mg/day.
Manic episode: The starting dose is 15mg as a single daily dose in monotherapy or 10mg daily in combination therapy.
Preventing recurrence in bipolar disorder: The recommended starting dose is 10mg/day. For patients who have been receiving Ferzapin for treatment of manic episode, continue therapy for preventing recurrence at the same dose. If a new manic, mixed, or depressive episode occurs, Ferzapin treatment should be continued (with dose optimization as needed), with supplementary therapy to treat mood symptoms, as clinically indicated.
During treatment for schizophrenia, manic episode, and recurrence prevention in bipolar disorder, daily dosage may subsequently be adjusted on the basis of individual clinical status within the range 5-20mg/day. An increase to a dose greater than the recommended starting dose is advised only after appropriate clinical reassessment and should generally occur at intervals of not less than 24 hours. Ferzapin can be given without regard for meals, as absorption is not affected by food. Gradual tapering of the dose should be considered when discontinuing Ferzapin.
Patients with renal and/or hepatic impairment:
A lower starting dose (5 mg) should be considered for such patients. In cases of moderate hepatic insufficiency (cirrhosis, Child-Pugh Class A or B), the starting dose should be 5 mg and only increased with caution.